Loading company…
Yisheng Biopharma develops biotherapeutics and vaccines for cancer and infectious diseases using PIKA® technology.
Founded in 1994 and based in Beijing, Yisheng Biopharma develops biotherapeutics and vaccines for cancer and infectious diseases using PIKA® immunomodulating technology. Its commercialized YSJA™ rabies vaccine has served over 16 million patients in China; other candidates address solid tumors, hepatitis B, and Covid-19. The company raised USD 130 million in Series B funding co-led by Oceanpine Capital and OrbiMed Advisors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in